Search results
Results from the WOW.Com Content Network
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Aricept – used to slow the progression of Alzheimer's disease Ativan ( lorazepam ) – a benzodiazepine , used to treat anxiety Asendin ( amoxapine ) – an dibenzoxazepine antidepressant
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. [ 10 ] [ 11 ] [ 8 ] It is taken by mouth . [ 10 ] [ 8 ]
The Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals, more commonly known by its abbreviation CPS, [1] is a reference book that contains drug monographs and numerous features which help healthcare professionals prescribe and use drugs safely and appropriately.
[196] [197] The combination of memantine and donepezil [198] has been shown to be "of statistically significant but clinically marginal effectiveness". [199] An extract of Ginkgo biloba known as EGb 761 has been used for treating AD and other neuropsychiatric disorders. [200] Its use is approved throughout Europe. [201]
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
In a large clinical trial of the rivastigmine patch in 1,195 patients with Alzheimer's disease, the target dose of 9.5 mg/24-hour patch provided similar clinical effects (e.g. memory and thinking, activities of daily living, concentration) as the highest doses of rivastigmine capsules, but with one-third fewer reports of nausea and vomiting. [8]